What is PARK HA BIOLOGICAL TECHNOLOGY's earnings per share (EPS)?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) reported diluted earnings per share of $-41.38 for fiscal year 2025. This represents a -4410.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

PARK HA BIOLOGICAL TECHNOLOGY Financials

BYAH

Source SEC Filings (10-K/10-Q) Updated Oct 31, 2025 Currency USD FYE October

This page shows PARK HA BIOLOGICAL TECHNOLOGY (BYAH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BYAH FY2025 2026-04-22

Park Ha’s core product economics remained rich, but overhead expansion rather than production cost drove the FY2025 breakdown.

From FY2023 through FY2025, gross margin stayed above 87.0% and operating cash flow stayed positive, so the underlying revenue still turned into gross profit and some cash. The FY2025 net loss of -$24.4M coincided with selling and administrative expense of $25.5M, which means the damage came from overhead and other operating costs, not from making the product itself.

FY2025 ended with cash of $3.8M, but financing cash flow contributed $3.7M; the stronger liquidity position was funded from outside the business rather than earned during the year. With liabilities still below equity, that support did not come with an obviously debt-heavy balance-sheet posture.

This is still a low-capital-intensity model: capital spending was only $88.8K in FY2025, so free cash flow drifting to -$3.0K points to operating disruption rather than a business that suddenly needed heavy reinvestment. The earlier cash-flow swing also suggests working-capital timing can reshape reported cash generation from one year to the next, making cash conversion less stable than the gross margin line implies.

Financial Health Signals

Financial Profile 40/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of PARK HA BIOLOGICAL TECHNOLOGY's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

PARK HA BIOLOGICAL TECHNOLOGY has an operating margin of -956.5%, meaning the company retains $-956 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from 33.3% the prior year.

Growth

PARK HA BIOLOGICAL TECHNOLOGY's revenue grew 6.0% year-over-year to $2.5M, a solid pace of expansion. This earns a growth score of 36/100.

Leverage

PARK HA BIOLOGICAL TECHNOLOGY carries a low D/E ratio of 0.49, meaning only $0.49 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

PARK HA BIOLOGICAL TECHNOLOGY's current ratio of 2.92 indicates adequate short-term liquidity, earning a score of 56/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While PARK HA BIOLOGICAL TECHNOLOGY generated $86K in operating cash flow, capex of $89K consumed most of it, leaving -$3K in free cash flow. This results in a low score of 55/100, reflecting heavy capital investment rather than weak cash generation.

Returns

PARK HA BIOLOGICAL TECHNOLOGY generates a -609.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from 31.8% the prior year.

Piotroski F-Score Neutral

4/9

PARK HA BIOLOGICAL TECHNOLOGY passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

-0.00x

For every $1 of reported earnings, PARK HA BIOLOGICAL TECHNOLOGY generates $-0.00 in operating cash flow ($86K OCF vs -$24.4M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-588997.6x

PARK HA BIOLOGICAL TECHNOLOGY earns $-588997.6 in operating income for every $1 of interest expense (-$24.1M vs $41). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.5M

YoY+6.0%

PARK HA BIOLOGICAL TECHNOLOGY generated $2.5M in revenue in fiscal year 2025. This represents an increase of 6.0% from the prior year.

EBITDA

-$24.0M

YoY-3044.6%

PARK HA BIOLOGICAL TECHNOLOGY's EBITDA was -$24.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 3044.6% from the prior year.

Net Income

-$24.4M

YoY-5191.3%

PARK HA BIOLOGICAL TECHNOLOGY reported -$24.4M in net income in fiscal year 2025. This represents a decrease of 5191.3% from the prior year.

EPS (Diluted)

$-41.38

YoY-4410.4%

PARK HA BIOLOGICAL TECHNOLOGY earned $-41.38 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 4410.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$3K

YoY-100.3%

PARK HA BIOLOGICAL TECHNOLOGY generated -$3K in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 100.3% from the prior year.

Cash & Debt

$3.8M

YoY+591.8%

PARK HA BIOLOGICAL TECHNOLOGY held $3.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

94.4%

YoY+2.6pp

PARK HA BIOLOGICAL TECHNOLOGY's gross margin was 94.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.6 percentage points from the prior year.

Operating Margin

-956.5%

YoY-989.8pp

PARK HA BIOLOGICAL TECHNOLOGY's operating margin was -956.5% in fiscal year 2025, reflecting core business profitability. This is down 989.8 percentage points from the prior year.

Net Margin

-965.0%

YoY-985.1pp

PARK HA BIOLOGICAL TECHNOLOGY's net profit margin was -965.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 985.1 percentage points from the prior year.

Return on Equity

-609.9%

YoY-641.7pp

PARK HA BIOLOGICAL TECHNOLOGY's ROE was -609.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 641.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$238K

YoY+548.8%

PARK HA BIOLOGICAL TECHNOLOGY invested $238K in research and development in fiscal year 2025. This represents an increase of 548.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$89K

YoY+3.8%

PARK HA BIOLOGICAL TECHNOLOGY invested $89K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 3.8% from the prior year.

BYAH Income Statement

Metric	FY25	FY24	FY23	FY22
Revenue	$2.5M+6.0%	$2.4M-3.1%	$2.5M+28.1%	$1.9M
Cost of Revenue	$143K-27.0%	$195K-37.2%	$311K-38.9%	$509K
Gross Profit	$2.4M+9.0%	$2.2M+1.8%	$2.1M+52.3%	$1.4M
R&D Expenses	$238K+548.8%	$37K+18.9%	$31K-49.1%	$61K
SG&A Expenses	$25.5M+3027.4%	$815K+68.0%	$485K-31.5%	$707K
Operating Income	-$24.1M-3142.5%	$794K-32.8%	$1.2M+499.2%	$197K
Interest Expense	$41	N/A	N/A	$194
Income Tax	$281K-10.9%	$315K-4.5%	$330K+25684.4%	-$1K
Net Income	-$24.4M-5191.3%	$479K-43.8%	$852K+345.4%	$191K
EPS (Diluted)	$-41.38-4410.4%	$0.96-43.5%	$1.70+16900.0%	$0.01

Metric	Q4'25	Q2'25	Q4'24	Q4'23
Revenue	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A

BYAH Balance Sheet

Metric	FY25	FY24	FY23	FY22
Total Assets	$6.0M+93.1%	$3.1M+36.1%	$2.3M	N/A
Current Assets	$5.5M+93.4%	$2.8M+30.7%	$2.2M	N/A
Cash & Equivalents	$3.8M+591.8%	$547K-47.0%	$1.0M+79.9%	$575K
Inventory	$75K+5.2%	$71K-25.4%	$96K	N/A
Accounts Receivable	$256K-22.7%	$331K-8.5%	$362K	N/A
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$2.0M+24.1%	$1.6M+25.9%	$1.3M	N/A
Current Liabilities	$1.9M+23.4%	$1.5M+22.7%	$1.2M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	$4.0M+165.2%	$1.5M+48.8%	$1.0M+573.7%	$150K
Retained Earnings	-$24.2M-8996.0%	$272K+358.3%	-$105K	N/A

Metric	Q4'25	Q2'25	Q4'24	Q4'23
Total Assets	$6.0M+2.1%	$5.8M+89.2%	$3.1M+36.1%	$2.3M
Current Assets	$5.5M-1.5%	$5.6M+96.3%	$2.8M+30.7%	$2.2M
Cash & Equivalents	$3.8M+180.3%	$1.4M+146.8%	$547K-47.0%	$1.0M
Inventory	$75K+14.3%	$66K-7.9%	$71K-25.4%	$96K
Accounts Receivable	$256K+107.6%	$123K-62.8%	$331K-8.5%	$362K
Goodwill	N/A	N/A	N/A	N/A
Total Liabilities	$2.0M+23.8%	$1.6M+0.3%	$1.6M+25.9%	$1.3M
Current Liabilities	$1.9M+23.9%	$1.5M-0.4%	$1.5M+22.7%	$1.2M
Long-Term Debt	N/A	N/A	N/A	N/A
Total Equity	$4.0M-6.0%	$4.3M+182.2%	$1.5M+48.8%	$1.0M
Retained Earnings	-$24.2M-23.6%	-$19.6M-7298.3%	$272K+358.3%	-$105K

BYAH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22
Operating Cash Flow	$86K-91.1%	$960K+659.0%	$127K-91.2%	$1.4M
Capital Expenditures	$89K+3.8%	$86K+277.4%	$23K+90.7%	$12K
Free Cash Flow	-$3K-100.3%	$875K+742.4%	$104K-92.7%	$1.4M
Investing Cash Flow	-$573K-12.7%	-$508K-149.7%	$1.0M+166.1%	-$1.5M
Financing Cash Flow	$3.7M+490.2%	-$957K-41.4%	-$677K-201.1%	$670K
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q4'23
Operating Cash Flow	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A

BYAH Financial Ratios

Metric	FY25	FY24	FY23	FY22
Gross Margin	94.4%+2.6pp	91.8%+4.4pp	87.4%+13.9pp	73.5%
Operating Margin	-956.5%-989.8pp	33.3%-14.7pp	48.0%+37.8pp	10.3%
Net Margin	-965.0%-985.1pp	20.1%-14.6pp	34.6%+24.7pp	10.0%
Return on Equity	-609.9%-641.7pp	31.8%-52.4pp	84.2%-43.1pp	127.3%
Return on Assets	-409.3%-424.8pp	15.5%-22.1pp	37.6%	N/A
Current Ratio	2.92+1.1	1.87+0.1	1.75	N/A
Debt-to-Equity	0.49-0.6	1.05-0.2	1.24	N/A
FCF Margin	-0.1%-36.9pp	36.7%+32.5pp	4.2%-70.3pp	74.5%

Metric	Q4'25	Q2'25	Q4'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A
Current Ratio	2.92-0.8	3.68+1.8	1.87+0.1	1.75
Debt-to-Equity	0.49+0.1	0.37-0.7	1.05-0.2	1.24
FCF Margin	N/A	N/A	N/A	N/A

Frequently Asked Questions

What is PARK HA BIOLOGICAL TECHNOLOGY's annual revenue?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) reported $2.5M in total revenue for fiscal year 2025. This represents a 6.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is PARK HA BIOLOGICAL TECHNOLOGY's revenue growing?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) revenue grew by 6% year-over-year, from $2.4M to $2.5M in fiscal year 2025.

Is PARK HA BIOLOGICAL TECHNOLOGY profitable?

No, PARK HA BIOLOGICAL TECHNOLOGY (BYAH) reported a net income of -$24.4M in fiscal year 2025, with a net profit margin of -965.0%.

What is PARK HA BIOLOGICAL TECHNOLOGY's EBITDA?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) had EBITDA of -$24.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is PARK HA BIOLOGICAL TECHNOLOGY's gross margin?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) had a gross margin of 94.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is PARK HA BIOLOGICAL TECHNOLOGY's operating margin?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) had an operating margin of -956.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is PARK HA BIOLOGICAL TECHNOLOGY's net profit margin?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) had a net profit margin of -965.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is PARK HA BIOLOGICAL TECHNOLOGY's return on equity (ROE)?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) has a return on equity of -609.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is PARK HA BIOLOGICAL TECHNOLOGY's free cash flow?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) generated -$3K in free cash flow during fiscal year 2025. This represents a -100.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is PARK HA BIOLOGICAL TECHNOLOGY's operating cash flow?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) generated $86K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are PARK HA BIOLOGICAL TECHNOLOGY's total assets?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) had $6.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are PARK HA BIOLOGICAL TECHNOLOGY's capital expenditures?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) invested $89K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does PARK HA BIOLOGICAL TECHNOLOGY spend on research and development?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) invested $238K in research and development during fiscal year 2025.

What is PARK HA BIOLOGICAL TECHNOLOGY's current ratio?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) had a current ratio of 2.92 as of fiscal year 2025, which is generally considered healthy.

What is PARK HA BIOLOGICAL TECHNOLOGY's debt-to-equity ratio?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) had a debt-to-equity ratio of 0.49 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is PARK HA BIOLOGICAL TECHNOLOGY's return on assets (ROA)?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) had a return on assets of -409.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is PARK HA BIOLOGICAL TECHNOLOGY's Piotroski F-Score?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are PARK HA BIOLOGICAL TECHNOLOGY's earnings high quality?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) has an earnings quality ratio of -0.00x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can PARK HA BIOLOGICAL TECHNOLOGY cover its interest payments?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) has an interest coverage ratio of -588997.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is PARK HA BIOLOGICAL TECHNOLOGY?

PARK HA BIOLOGICAL TECHNOLOGY (BYAH) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.